ADCT Stock Overview
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors.
ADC Therapeutics SA Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$8.12|
|52 Week High||US$32.00|
|52 Week Low||US$5.52|
|1 Month Change||-10.87%|
|3 Month Change||9.88%|
|1 Year Change||-69.36%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-72.61%|
Recent News & Updates
ADC Therapeutics Non-GAAP EPS of -$0.73, revenue of $17.29M misses by $13.93M
ADC Therapeutics press release (NYSE:ADCT): Q2 Non-GAAP EPS of -$0.73. Revenue of $17.29M (+359.8% Y/Y) misses by $13.93M. “The ZYNLONTA® launch is advancing steadily as we continue to increase awareness and advocacy. There is significant opportunity ahead and we have a focused plan in place to achieve continued growth in the coming quarters,” commented Ameet Mallik, Chief Executive Officer of ADC Therapeutics. “Our pipeline of hematology and solid tumor programs is progressing well with impressive Cami Phase 2 data in Hodgkin lymphoma presented at the EHA Congress in June. Our recent license agreement with Sobi® in Europe gives us worldwide access for ZYNLONTA. We have a strong cash runway extending into early 2025 which makes us well-positioned to execute on our key objectives.”
Analysts Just Made A Meaningful Upgrade To Their ADC Therapeutics SA (NYSE:ADCT) Forecasts
Shareholders in ADC Therapeutics SA ( NYSE:ADCT ) may be thrilled to learn that the analysts have just delivered a...
|ADCT||US Biotechs||US Market|
Return vs Industry: ADCT underperformed the US Biotechs industry which returned -22.1% over the past year.
Return vs Market: ADCT underperformed the US Market which returned -11.6% over the past year.
|ADCT Average Weekly Movement||10.7%|
|Biotechs Industry Average Movement||12.6%|
|Market Average Movement||7.9%|
|10% most volatile stocks in US Market||17.0%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: ADCT is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: ADCT's weekly volatility (11%) has been stable over the past year.
About the Company
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second-line transplant-ineligible patients; and Phase I clinical trial for treatment of relapsed or refractory non-hodgkin lymphoma (NHL). The company is also developing camidanlumab tesirine, an ADC that has completed Phase I clinical trial to treat relapsed or refractory NHL; in Phase II clinical trial in relapsed or refractory hodgkin lymphoma; and in Phase Ib clinical trial for selected advanced solid tumors.
ADC Therapeutics SA Fundamentals Summary
|ADCT fundamental statistics|
Is ADCT overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ADCT income statement (TTM)|
|Cost of Revenue||US$160.21m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-2.43|
|Net Profit Margin||-199.01%|
How did ADCT perform over the long term?See historical performance and comparison